January 2024

DOVER, Del., Jan. 29, 2024 /PRNewswire/ — Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the clearance from

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: